Abstract
A new, observational study suggests that aspirin only marginally increases the bleeding risk in patients with diabetes mellitus, perhaps reflecting impaired platelet inhibition. Inconclusive evidence from small, randomized trials and mechanistic studies reinforces the need for larger trials to determine the relative cardioprotective benefits and bleeding risks of aspirin in these patients.
Lingua originale | English |
---|---|
pagine (da-a) | 495-496 |
Numero di pagine | 2 |
Rivista | NATURE REVIEWS. CARDIOLOGY |
Volume | 9 |
DOI | |
Stato di pubblicazione | Pubblicato - 2012 |
Pubblicato esternamente | Sì |
Keywords
- aspirin
- diabetes